Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes-Reference-Cited by-同舟云学术

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes

Published:2021-06-04 Issue:6546 Volume:372 Page:1108-1112
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Voss William N.¹^ORCID,Hou Yixuan J.²^ORCID,Johnson Nicole V.¹^ORCID,Delidakis George³^ORCID,Kim Jin Eyun⁴^ORCID,Javanmardi Kamyab¹^ORCID,Horton Andrew P.¹^ORCID,Bartzoka Foteini¹,Paresi Chelsea J.⁵^ORCID,Tanno Yuri³^ORCID,Chou Chia-Wei¹^ORCID,Abbasi Shawn A.⁶^ORCID,Pickens Whitney¹,George Katia¹^ORCID,Boutz Daniel R.¹⁷^ORCID,Towers Dalton M.³,McDaniel Jonathan R.⁸^ORCID,Billick Daniel¹^ORCID,Goike Jule¹,Rowe Lori⁹¹⁰^ORCID,Batra Dhwani⁹,Pohl Jan⁹,Lee Justin⁹^ORCID,Gangappa Shivaprakash¹¹,Sambhara Suryaprakash¹¹^ORCID,Gadush Michelle¹²^ORCID,Wang Nianshuang¹^ORCID,Person Maria D.¹²^ORCID,Iverson Brent L.⁵^ORCID,Gollihar Jimmy D.¹⁷¹³,Dye John M.⁶^ORCID,Herbert Andrew S.⁶^ORCID,Finkelstein Ilya J.¹^ORCID,Baric Ralph S.²¹⁴^ORCID,McLellan Jason S.¹^ORCID,Georgiou George¹³⁴¹⁵^ORCID,Lavinder Jason J.¹³^ORCID,Ippolito Gregory C.¹¹³¹⁵^ORCID

Affiliation:

1. Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.

2. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

3. Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.

4. Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.

5. Department of Chemistry, The University of Texas at Austin, Austin, TX, USA.

6. U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.

7. CCDC Army Research Laboratory-South, The University of Texas at Austin, Austin, TX, USA.

8. Biomedicine Design, Pfizer, Cambridge, MA, USA.

9. Biotechnology Core Facility Branch, Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

10. Tulane National Primate Research Center Department of Microbiology 18703 Three Rivers Road Covington, LA, USA.

11. Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

12. Center for Biomedical Research Support, The University of Texas at Austin, Austin, TX, USA.

13. Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.

14. Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

15. Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.

Abstract

A public anti-COVID antibody repertoire Most analyses of the antibody responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have focused on antibodies cloned from memory B cells. This approach has led researchers to conclude that neutralizing antibodies (nAbs) primarily target the receptor-binding domain (RBD) of the virus's spike protein. Voss et al. took a different approach, using proteomic deconvolution of the serum immunoglobulin G antibody repertoire from four COVID-19 convalescent patients. They found that the nAb response was largely directed against epitopes such as the N-terminal domain (NTD), which lie outside the RBD. Several of these nAbs were shared among donors and targeted an NTD epitope that is frequently mutated by variants of concern. Science , abg5268, this issue p. 1108

Funder

National Cancer Institute

National Institute of Allergy and Infectious Diseases

University of California, San Francisco

United States Army Medical Research Institute of Infectious Diseases

College of Natural Sciences, University of Texas at Austin

Welch Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference54 articles.